Moreover, among AML subgroups defined by molecular abnormalities, we identified patients with NPM1 mutations (in the absence of a FLT3 mutation) to be correlated with having EPR+ after induction cycle 1. This evidence concerns the gene FLT3 and acute myeloid leukemia.